Dabur India shares are set to be in focus after the US FDA issued an import alert on drugs manufactured at its Silvassa plant, citing data integrity lapses. The company said the impact is limited to a small portion of operations, while broader business and domestic sales remain unaffected.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets